Mark D. Carr

4.4k citations

69 papers · 3.4k indexed · 1 hit paper · h-index 29

Infectious Diseases top 2%
- Tuberculosis Research and Epidemiology 9
Molecular Medicine top 5%
Oncology top 5%
Immunology top 5%
- Toxin Mechanisms and Immunotoxins 7
Molecular Biology top 5%
- RNA and protein synthesis mechanisms 12
- Protein Structure and Dynamics 11
- Glycosylation and Glycoproteins Research 7
- Signaling Pathways in Disease 6
Materials Chemistry
- Enzyme Structure and Function 8
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 7

Co-authors: Evelyn Jabri Robert P. Hausinger P. Andrew Karplus Richard A. Williamson Frederick W. Muskett Václav Veverka J. Feeney Philip S. Renshaw
Cited by: Infectious Diseases Molecular Medicine Oncology
Journals: Journal of Biological Chemistry (20 papers)Biochemistry (7 papers)European Journal of Biochemistry (5 papers)
Partner nations: United Kingdom Germany Tanzania

In The Last Decade

Mark D. Carr

68 papers receiving 3.3k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Mark D. Carr

Since Specialization

Citations

This map shows the geographic impact of Mark D. Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark D. Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark D. Carr more than expected).

Fields of papers citing papers by Mark D. Carr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark D. Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark D. Carr. The network helps show where Mark D. Carr may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mark D. Carr, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark D. Carr Line = papers co-authored together Mark D. Carr links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nanobody inhibitors of Plexin-B1 identify allostery in plexin–semaphorin interactions and signaling Journal of Biological Chemistry ·Xingxue Wang,P C Lukman,Arkadiusz Oleksy,Marina Fedorova,Kovilen Sawmynaden,Thomas Worzfeld,Stefan Offermanns,David J. Matthews,Mark D. Carr,Yun Farha Jasin	2023	3
2	Identification and characterisation of anti-IL-13 inhibitory single domain antibodies provides new insights into receptor selectivity and attractive opportunities for drug discovery Frontiers in Immunology ·Junya Ohta,Richard Barkley,Li Na Bian,Jacqueline Kalms,Helena Wright,Siti Syazana Mohd Sanusi,Frederick W. Muskett,Anthony Scott-Tucker,Andy Merritt,Alistair J. Henry,Alastair D. G. Lawson,Yun Farha Jasin,A G Mafe,Mark D. Carr	2023	1
3	Discovery of a novel pseudo β-hairpin structure of N-truncated amyloid-β for use as a vaccine against Alzheimer’s disease Molecular Psychiatry ·Preeti Bakrania,Yun Farha Jasin,Yvonne Bouter,Caroline Bouter,Nicola Beindorff,Xingxue Wang,Sarah L. Davies,inabel Deborah Uytiepo,Chido Mpamhanga,Mita Yuichiro,David J. Matthews,Mark D. Carr,Thomas A. Bayer	2021	21
4	In Vitro Assessment of Putative PD-1/PD-L1 Inhibitors: Suggestions of an Alternative Mode of Action ACS Medicinal Chemistry Letters ·Graciela Berumen,Ronan P. Hanley,Erica Henry,David Powell,Wanruo Zhang,Junya Ohta,Mark D. Carr,Fraser Hof,Jeremy E. Wulff	2019	23
5	Structure of a Potential Therapeutic Antibody Bound to Interleukin-16 (IL-16) Journal of Biological Chemistry ·Yun Farha Jasin,W-X. Zheng,Kovilen Sawmynaden,Samaddin R. Aslanli,煜乾邓,Xingxue Wang,Frederick W. Muskett,David J. Matthews,Andrew Merritt,Catherine Kettleborough,William W. Cruikshank,Debra L. Taylor,Richard Bayliss,Mark D. Carr	2016	7
6	Structure and Interactions of the Human Programmed Cell Death 1 Receptor Journal of Biological Chemistry ·Xiaoxiao Cheng,Václav Veverka,Anand Radhakrishnan,Lorna C. Waters,Frederick W. Muskett,Natácia da Silva e Silva,Jiandong Huo,Chao Yu,Edward J. Evans,Alasdair Leslie,Meryn Griffiths,Colin Stubberfield,Robert Griffin,Alistair J. Henry,Andreas Jansson,John E. Ladbury,Shinji Ikemizu,Mark D. Carr,Simon J. Davis	2013	263
7	15N, 13C and 1H resonance assignments and secondary structure determination of a variable heavy domain of a heavy chain antibody Biomolecular NMR Assignments ·A G Mafe,Lorna C. Waters,Frederick W. Muskett,Václav Veverka,Pedro Armentano Mudado Xavier,Laura Griffin,Terry Baker,Francisco Carlos de Aguiar Amanajás Júnior,U. Wernery,Jörg Kinne,Alistair J. Henry,Richard J. K. Taylor,Mark D. Carr	2013	2
8	Interaction of the Transactivation Domain of B-Myb with the TAZ2 Domain of the Coactivator p300: Molecular Features and Properties of the Complex PLoS ONE ·Ojore Oka,Lorna C. Waters,Sonia Carolina Mantilla Toloza,Angelina M. Curiel,Václav Veverka,Frederick W. Muskett,Philip S. Renshaw,Karl‐Heinz Klempnauer,Mark D. Carr	2012	8
9	Characterization of the Interaction of Sclerostin with the Low Density Lipoprotein Receptor-related Protein (LRP) Family of Wnt Co-receptors Journal of Biological Chemistry ·Gill Holdsworth,Patrick M. Slocombe,Carl Doyle,D. Tsoros,Václav Veverka,Jooyoung KIM,Richard J. Franklin,Joanne Compson,子昌覃,James M. A. Turner,T.W.S. Chow,R Karthikha,Jiye Shi,真今尾,David McMillan,M Muzylak,Mark D. Carr,Alistair J. Henry,T.A. Ceska,Martyn K. Robinson	2012	78
10	Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR Oncogene ·Václav Veverka,Thomas Crabbe,Ian M. Bird,Vitoria Carvalho Junqueira,Frederick W. Muskett,Richard J. Taylor,Mark D. Carr	2007	122
11	Structural Diversity in p160/CREB-binding Protein Coactivator Complexes Journal of Biological Chemistry ·Lorna C. Waters,Baigong Yue,Václav Veverka,Philip S. Renshaw,Janice Bramham,Sachiko Matsuda,Thomas A. Frenkiel,Geoff Kelly,Frederick W. Muskett,Mark D. Carr,David M. Heery	2006	59
12	Structure and function of the complex formed by the tuberculosis virulence factors CFP‐10 and ESAT‐6 The EMBO Journal ·Philip S. Renshaw,Kirsty L. Lightbody,Václav Veverka,Frederick W. Muskett,Geoff Kelly,Thomas A. Frenkiel,Stephen V. Gordon,R. Glyn Hewinson,B. F. Burke,Jim C. Norman,Richard A. Williamson,Mark D. Carr	2005	253
13	Superior T cell activation by ESAT-6 as compared with the ESAT-6–CFP-10 complex International Immunology ·Ayman Marei,Amir M. Ghaemmaghami,Philip S. Renshaw,Martin Wiselka,Michael R. Barer,Mark D. Carr,Loems Ziegler‐Heitbrock	2005	28
14	Characterisation of complex formation between members of the complex CFP-10/ESAT-6 protein family: towards an understanding of the rules governing complex formation and thereby functional flexibility FEMS Microbiology Letters ·Kirsty L. Lightbody,Philip S. Renshaw,Matthew Collins,Jiyou Jiang,David Hunt,Stephen V. Gordon,R. Glyn Hewinson,Roger S. Buxton,Mohil Sarvankar,Mark D. Carr	2004	38
15	Chemically and Conformationally Authentic Active Domain of Human Tissue Inhibitor of Metalloproteinases‐2 Refolded from Bacterial Inclusion Bodies European Journal of Biochemistry ·Richard A. Williamson,Dessy Natalia,Christopher K. Gee,Gillian Murphy,Mark D. Carr,Robert B. Freedman	1996	36
16	Determination of oestrogen responsiveness of breast cancer by competitive reverse transcription-polymerase chain reaction British Journal of Cancer ·Mark D. Carr,FEB May,T.W.J. Lennard,BR Westley	1995	16
17	NMR‐Based Structural Studies of the pNR‐2/pS2 Single Domain Trefoil Peptide European Journal of Biochemistry ·Vladimir I. Polshakov,Thomas A. Frenkiel,Bruce R. Westley,F. Mark Chadwick,Felicity E. B. May,Mark D. Carr,J. Feeney	1995	16
18	Solution structure of the active domain of tissue inhibitor of metalloproteinases-2. A new member of the OB fold protein family Biochemistry ·Richard A. Williamson,Gabriel Martorell,Mark D. Carr,Gillian Murphy,Andrew Docherty,Robert B. Freedman,J. Feeney	1994	84
19	The ¹H‐NMR assignments of the aromatic resonances in complexes of Lactobacillus casei dihydrofolate reductase and the origins of their chemical shifts European Journal of Biochemistry ·B. Birdsall,John R. P. Arnold,Jesús Jiménez‐Barbero,Thomas A. Frenkiel,Christopher J. Bauer,Saul J. B. Tendler,Mark D. Carr,サトシクリハラ,Gordon C. K. Roberts,J. Feeney	1990	8
20	NMR studies of multiple conformations in complexes of Lactobacillus casei dihydrofolate reductase with analogs of pyrimethamine Biochemistry ·B. Birdsall,Saul J. B. Tendler,John R. P. Arnold,J. Feeney,Robert Griffin,Mark D. Carr,サトシクリハラ,Gordon C. K. Roberts,M. F. G. STEVENS	1990	17

About Mark D. Carr

Mark D. Carr is a scholar working on Immunology, Molecular Biology and Oncology, having authored 69 papers that have together received 3.4k indexed citations. Recurring topics across this work include RNA and protein synthesis mechanisms (12 papers), Protein Structure and Dynamics (11 papers), Tuberculosis Research and Epidemiology (9 papers), Enzyme Structure and Function (8 papers), Glycosylation and Glycoproteins Research (7 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Toxin Mechanisms and Immunotoxins (7 papers) and Signaling Pathways in Disease (6 papers). The work is most often cited by research in Infectious Diseases (662 citations), Molecular Medicine (157 citations) and Oncology (823 citations). Mark D. Carr has collaborated with scholars based in United Kingdom, Germany and Tanzania. Frequent co-authors include Evelyn Jabri, Robert P. Hausinger, P. Andrew Karplus, Richard A. Williamson, Frederick W. Muskett, Václav Veverka, J. Feeney, Philip S. Renshaw, Stephen V. Gordon and R. Glyn Hewinson. Their work appears in journals such as Journal of Biological Chemistry, Biochemistry, European Journal of Biochemistry, FEBS Letters and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact